Addiction Science & Clinical Practice is a premier open-access journal dedicated to advancing the understanding and treatment of addiction through evidence-based research and clinical practice. Published by BMC in the United Kingdom since 2007, this journal has significantly impacted the fields of Clinical Psychology, Medicine, and Psychiatry and Mental Health, proudly securing a Q1 ranking in multiple categories as of 2023. With an emphasis on high-quality research, the journal provides an inclusive platform for the dissemination of innovative findings and clinical insights that address the complexities of addiction. Researchers, practitioners, and students alike benefit from its unrestricted access since 2012, allowing for widespread dissemination of knowledge. Located at CAMPUS, 4 CRINAN ST, LONDON N1 9XW, the journal continues to lead the way in fostering collaboration and informing best practices in addiction science.

ADDICTION, published by Wiley, is a highly regarded academic journal that serves the vibrant fields of Medicine and Psychiatry and Mental Health. With an impressive impact factor reflective of its significance—ranking in the top 8% and 7.5% of its categories respectively—this journal is esteemed for its rigorous peer-reviewed research which spans a wide array of topics related to addiction, including pharmacology, prevention, and treatment modalities. Since its inception in 1993, ADDICTION has continually provided a platform for innovative research, shaping the discourse and influencing clinical practices worldwide. This journal, based in the United Kingdom at a prestigious location in Hoboken, NJ, stands as a beacon for researchers, practitioners, and students alike, committed to advancing understanding and strategies to combat addiction-related challenges. Although it is not an Open Access publication, the journal's contribution to the field remains invaluable, ensuring that cutting-edge findings are disseminated widely among professionals dedicated to improving mental health outcomes.

The JOURNAL OF CLINICAL PSYCHIATRY is a premier publication dedicated to advancing the understanding and treatment of psychiatric disorders. Established in 1978 and published by Physicians Postgraduate Press, this esteemed journal provides a vital platform for researchers, clinicians, and mental health professionals to share innovative findings and evidence-based practices in psychiatry. With an impressive impact factor and recognized as a Q1 journal in both Medicine (miscellaneous) and Psychiatry and Mental Health, the journal ranks among the top in its field, sitting at 96th out of 567 in Scopus rankings, placing it in the 83rd percentile. The journal's commitment to high-quality, peer-reviewed articles facilitates the dissemination of knowledge crucial for advancing clinical practices and improving patient outcomes. Access to its latest research is offered through institutional subscriptions, making it an essential resource for anyone involved in the mental health sector, from seasoned practitioners to aspiring students.

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, an esteemed publication from Lippincott Williams & Wilkins, serves as a vital resource in the fields of pharmacology and psychiatry. With a notable Q2 ranking in both the medical pharmacology and psychiatry categories, this journal facilitates the dissemination of significant findings related to psychopharmacological research, clinical practices, and advancements in mental health treatment. The journal has been committed to publishing high-quality, peer-reviewed articles since its inception in 1981, covering a wide scope of topics crucial for professionals, researchers, and students alike. With a current impact factor and burgeoning interest from the academic community, the JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY is essential for anyone engaged in the study or practice of clinical psychopharmacology, providing insights that shape contemporary psychiatric medication strategies and improve patient outcomes. For access, please refer to the official publication channels.

PSYCHIATRY AND CLINICAL NEUROSCIENCES is a leading journal in the fields of psychiatry and clinical neurology, published by Wiley. With a commendable impact factor and a position within the prestigious Q1 quartile across multiple relevant categories—including Medicine (Miscellaneous), Neurology, and Psychiatry and Mental Health—this journal stands out for its rigorous peer-reviewed content that addresses critical issues in mental health and neurological disorders. Established in 1933, the journal has a rich history of contributing impactful research that guides both clinical practice and academic inquiry. Although it is not an open-access journal, its high relevance is underscored by its Scopus rankings, with notable percentiles in Psychiatry and Neurology, making it a vital resource for researchers, clinicians, and students looking to stay abreast of the latest advancements. Located in the United Kingdom, PSYCHIATRY AND CLINICAL NEUROSCIENCES aims to bridge the gap between theory and practical application, fostering a comprehensive understanding of the complex interplay between mental health and neurological conditions.

The Journal of Dual Diagnosis, published by Routledge Journals, Taylor & Francis Ltd, is a leading interdisciplinary platform dedicated to the critical study of co-occurring mental health and substance use disorders. With its ISSN 1550-4263 and E-ISSN 1550-4271, this esteemed journal has been at the forefront of advancing research and clinical practice since its inception in 2004, and continues to serve as a vital resource until 2024. Ranked in the second quartile (Q2) in Psychiatry and Mental Health and positioned at the 64th percentile in the Scopus rankings, it emphasizes the importance of integrating care across various domains of health. Although not open access, it offers a wealth of peer-reviewed articles, case studies, and reviews suitable for researchers, practitioners, and students alike, aiming to enhance our understanding and treatment of dual diagnosis. The journal's commitment to addressing the complexities of dual disorders not only informs research but also shapes policy and clinical guidelines, making it an essential read for anyone involved in these critical areas of mental health.

The Journal of Mental Health and Human Behaviour is a distinguished publication dedicated to advancing the field of mental health, focusing on innovative research and practical applications that enhance human behaviour and overall well-being. Published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, this journal has been an open-access platform since 2014, enabling wider dissemination of knowledge and fostering collaboration among researchers, professionals, and students globally. With an ISSN of 0971-8990 and E-ISSN 2543-1897, it aims to provide a comprehensive array of peer-reviewed articles that cover various facets of mental health, including psychological theories, therapeutic practices, and sociocultural influences. The journal plays an integral role in bridging the gap between research and practice, making it essential for those who are committed to improving mental health outcomes and advocating for human behaviour change. Published in India, the journal not only highlights regional issues but also contributes to international discussions on mental health trends and interventions, affirming its importance in a rapidly evolving field.

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, published by Lippincott Williams & Wilkins, stands as a pivotal peer-reviewed journal in the fields of pharmacology and psychiatry. Established in 1986, it has garnered a prominent reputation with a 2023 impact factor placing it in the Q2 category for both Pharmacology and Psychiatry and Mental Health. With an impressive Scopus ranking of #227 in the Psychiatry and Mental Health category and #114 in Pharmacology, it serves as an essential platform for researchers seeking to disseminate critical findings on psychopharmacological interventions and their clinical efficacy. The journal’s rigorous peer-review process ensures that only high-quality research is published, making it a trusted resource for professionals and students alike. By focusing on the latest advancements and evidence-based practices, the INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY contributes significantly to the understanding of mental health treatments, fostering ongoing dialogue and innovation in the discipline.

Psychology of Addictive Behaviors, published by the Educational Publishing Foundation of the American Psychological Association, is a distinguished peer-reviewed journal dedicated to advancing the understanding of addiction through rigorous psychological research. With an impressive impact factor and a reputation for excellence, this journal holds a prestigious Q1 quartile ranking in Clinical Psychology, Medicine (miscellaneous), and Psychiatry and Mental Health as of 2023. Since its inception in 1993, it has provided a vital platform for the dissemination of high-quality studies, fostering collaboration and knowledge exchange amidst researchers, clinicians, and students in the mental health arena. The journal is particularly noted for its comprehensive coverage of diverse topics related to addictive behaviors, thereby contributing significantly to the field's evidence base and clinical practices. Although currently not open access, its commitment to scholarly excellence ensures that subscribers benefit from invaluable insights into the complexities of addiction. With the culmination of research spanning from 1993 to 2024, Psychology of Addictive Behaviors stands as a cornerstone for those striving to understand and combat the challenges of addiction.

The INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, published by OXFORD UNIV PRESS, is a leading open-access journal in the fields of pharmacology and psychiatry, with an impressive impact factor reflecting its prominence in academic research. Since its inception in 1998, the journal has provided a crucial platform for the publication of high-quality research, offering insights into the effects of neuropharmacological agents on mental health. As of 2023, it ranks in the Q1 category for both Pharmacology and Psychiatry & Mental Health, underscoring its relevance and authority within the scientific community. With notable rankings in various medical subspecialties, it attracts contributions that advance our understanding of psychiatric disorders and therapeutic strategies. The accessible nature of the journal, following its transition to open access in 2015, has expanded its reach, making knowledge and findings readily available to researchers, professionals, and students globally. This commitment to disseminating impactful research ensures the journal remains at the forefront of neuropsychopharmacological advancements.